Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Dani P. Bolognesi
AddedMar 31, 2024
UpdatedMay 31, 2026
Dani P. Bolognesi

Dani P. Bolognesi

Co-Founder, Istari Oncology

Crunchbase

Dani P. Bolognesi's Career

Istari Oncology
Istari Oncology

Morrisville, NC, US

Co-Founder
b3 bio
b3 bio

Durham, NC, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Dani P. Bolognesi's Career

Istari Oncology
Istari Oncology
Series D$48.5M372014Morrisville, NC, US
Co-Founder

Leadership at Istari Oncology

Matthew StoberMatthew StoberCEO
Darell D BignerDarell D BignerCo-Founder
Matthias GromeierMatthias GromeierCo-Founder

Similar to Istari Oncology

Immune-Onc TherapeuticsImmune-Onc TherapeuticsPalo Alto, CA, USCancer Treatmentest. 2016Immune-Onc TherapeuticsPalo Alto, CA, US · est. 2016

California-based Immune-Onc Therapeutics develops therapeutic antibodies for cancer treatment.

Public · $140.1M35
Irazu OncologyIrazu OncologyBaltimore, MD, USCancer Vaccinesest. 2022Irazu OncologyBaltimore, MD, US · est. 2022

Baltimore-based medical organization pioneering superior cancer vaccine platforms for improved outcomes.

Seed · $2.6M5
MaveriX OncologyMaveriX OncologyPalo Alto, CA, USCancer Treatmentest. 2014MaveriX OncologyPalo Alto, CA, US · est. 2014

MaveriX: A global biotech firm innovating targeted cancer chemo-immunotherapies.

Series A · $6.5M2
Revitope OncologyRevitope OncologySan Francisco, CA, USCancer Immunotherapyest. 2014Revitope OncologySan Francisco, CA, US · est. 2014

Revitope Oncology: A biotech firm innovating precise cancer immunotherapies through protein engineering.

Series A · $8.5M32
b3 bio
b3 bio
Series A$5.7M62007Durham, NC, US
Co-Founder

Leadership at b3 bio

Robert J. BonczekRobert J. BonczekCo-Founder

Similar to b3 bio

ZenomicsZenomicsDurham, NC, USDrug Deliveryest. 2015ZenomicsDurham, NC, US · est. 2015

Zenomics: Innovating diabetes treatment through advanced drug delivery systems.

Seed · $2.8M8
Control Delivery SystemsControl Delivery SystemsWatertown, MA, USBiotechnologyControl Delivery SystemsWatertown, MA, US

Control Delivery Systems: A leading innovator in the biotechnology industry.

Series C · $34.5M50
BioQ PharmaBioQ PharmaSan Francisco, CA, USDrugs, Pharmaceuticalsest. 2003BioQ PharmaSan Francisco, CA, US · est. 2003

BioQ Pharma, a San Francisco-based specialty pharma company, develops ready-to-use infusible drugs to minimize medication errors globally.

Series B · $107.8M25
LayerBioLayerBioLexington, MA, USDrug Deliveryest. 2013LayerBioLexington, MA, US · est. 2013

Layerbio, Inc.: Innovating drug delivery solutions for wound care, orthopedics, and more.

Angel · $385k5

Dani P. Bolognesi's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoJB LEEJB LEECo-Founder · Kakao

People Similar to Dani P. Bolognesi

Brian ThompsonBrian ThompsonCo-Founder · 3BCDaniel CohenDaniel CohenCo-Founder & CEO · 3DBioPaul GrilloPaul GrilloFounder · BioGreen360David KidderDavid KidderCo-Founder · Alt Option ReturnRon TeitelbaumRon TeitelbaumCo-Founder · QwaqDaniel ChainDaniel ChainBoard Member · Intellect Neurosciences